RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
NK 细胞：癌症免疫治疗的下一波浪潮
英文原题：Natural killer cells: the next wave in cancer immunotherapy.
查看英文原题
Natural killer cells: the next wave in cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
聚焦于恢复T细胞活性的免疫疗法，如PD-1/PD-L1和CTLA-4阻断，前所未有地革新了癌症治疗格局。然而，此前研究不足的免疫系统组成部分——自然杀伤（NK）细胞，正成为免疫治疗研究的新焦点。本文综述NK细胞对现有免疫治疗成功的贡献，概述当前利用NK细胞治疗癌症的临床前和临床策略，并强调NK细胞介导疗法已成为下一波癌症免疫疗法的重要靶点。
展开英文摘要原文
Immunotherapies focusing on rejuvenating T cell activities, like PD-1/PD-L1 and CTLA-4 blockade, have unprecedentedly revolutionized the landscape of cancer treatment. Yet a previously underexplored component of the immune system - natural killer (NK) cell, is coming to the forefront of immunotherapeutic attempts.
In this review, we discuss the contributions of NK cells in the success of current immunotherapies, provide an overview of the current preclinical and clinical strategies at harnessing NK cells for cancer treatment, and highlight that NK cell-mediated therapies emerge as a major target in the next wave of cancer immunotherapy.
论文信息
- 作者
- Chen X、Jiang L、Liu X
- 单位
- Department of Biology, BeiGene (Beijing) Co., Ltd., Beijing, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 35967421 · DOI 10.3389/fimmu.2022.954804
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →